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BACKGROUND: Neurosurgical resection and whole-brain radiation therapy (WBRT) are accepted treatments for single and oligome-
tastatic cancer to the brain. To avoid the decline in neurocognitive function (NCF) linked to WBRT, the authors conducted a prospec-
tive, multicenter, phase 2 study to determine whether surgery and carmustine wafers (CW), while deferring WBRT, could preserve
NCF and achieve local control (LC). METHODS: NCF and LC were measured in 59 patients who underwent resection and received
CW for a single (83%) or dominant (oligometastatic, 2 to 3 lesions) metastasis and received stereotactic radiosurgery (SRS) for tiny
nodules not treated with resection plus CW. Preservation of NCF was defined as an improvement or a decline 1 standard deviation
from baseline in 3 domains: memory, executive function, and fine motor skills, evaluated at 2-month intervals. RESULTS: Significant
improvements in executive function and memory occurred throughout the 1-year follow-up. Preservation or improvement of NCF
occurred in all 3 domains for the majority of patients at each of the 2-month intervals. NCF declined in only 1 patient. The chemowa-
fers were well tolerated, and serious adverse events were reversible. There was local recurrence in 28% of the patients at 1-year fol-
low-up. CONCLUSIONS: Patients with brain metastases had improvements in their cognitive trajectory, especially memory and
executive function, after treatment with resection plus CW. The rate of LC (78%) was comparable to historic rates of surgery with
WBRT and superior to reports of WBRT alone. For patients who undergo resection for symptomatic or large-volume metastasis or for
tissue diagnosis, the addition of CW can be considered as an option. Cancer 2013;119:3830-8. VC 2013 The Authors. Cancer published
by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Com-
mons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is
properly cited, the use is non- commercial and no modifications or adaptations are made.
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INTRODUCTION
Brain metastases affect 25% to 45% of patients with cancer.1-3 The rising incidence of metastasis to the brain threatens to
limit gains made by new systemic treatments.4 Both the blood-tumor barrier and tumor-stromal interactions impede the
delivery of systemic drugs to tumors in the brain.3-5
Based on the trials of Patchell and colleagues,6,7 neurosurgical resection and whole-brain radiation therapy (WBRT)
are mainstays of current therapy.8-11 WBRT helps prevent local recurrence and new distant brain metastases,7,12-14 but it
fails to improve the duration of functional independence or overall survival.13,14 WBRT carries risks of neurocognitive
impairment, leukoencephalopathy, and brain atrophy.15-17 Thus, as patients with brain metastases live longer, increasing
concern regarding neurocognitive function (NCF) has led to a paradigm shift to defer WBRT and treat locally with sur-
gery and=or stereotactic radiosurgery (SRS) while monitoring for distant relapses.12,14,18,19
To enhance drug delivery, biodegradable carmustine polymer wafers (Gliadel; Eisai, Inc., Woodcliff Lake, NJ) were
developed to be implanted into the surgical cavity of malignant gliomas.20-22 Preclinical, orthotopic models demonstrated
prolonged survival and local control (LC) when carmustine wafers were used to treat brain metastases.23,24 In the only
published clinical trial that used carmustine wafers to treat brain metastases, we demonstrated excellent LC when carmus-
tine wafers were combined with resection and WBRT.25 Given the known NCF risks linked to WBRT,12,17-19 we
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designed the current study to evaluate the LC rate with
resection and chemowafers while deferring WBRT. We
hypothesized that NCF would be preserved or improved
as we monitored the “cognitive trajectory” after surgery.26
MATERIALS AND METHODS
This prospective, single-arm, phase 2 trial
(NCT00525590) involved 12 US centers between De-
cember 2007 and December 2010. The institutional
review board at each site approved the protocol, following
Good Clinical Practice guidelines and the Declaration of
Helsinki. All patients provided informed consent. A data
safety committee monitored the study.
Eligible patients had 1 to 3 brain metastases, includ-
ing patients with a single resectable metastasis or with 2
metastases that were resectable as 1 cavity (distance apart,
<1 cm); age >18 years; a Karnofsky performance status
(KPS) 70; and a recursive partitioning analysis (RPA)
classification of 1 (35%) or 2 (65%).1,27 The most com-
mon histology (41%) was nonsmall cell lung cancer.
Exclusion criteria included: small cell lung cancer, thyroid
cancer, lymphoma, germ cell cancer, or primary central
nervous system (CNS) tumor; prior cranial irradiation or
exposure to carmustine; leptomeningeal disease; surgically
targeted metastasis in brainstem or posterior fossa; preg-
nancy; unstable medical or psychiatric status; and receipt
of investigational drugs or bevacizumab within 30 days or
of anticoagulants within 7 days of entry.
Initially, the protocol included only patients with a
single cerebral metastasis, based on the assumption that
half of all metastases are single and, thus, are potentially
treatable by surgical resection.6 However, with modern
high-resolution magnetic resonance imaging (MRI)
scans, additional asymptomatic micrometastases that are
amenable to radiosurgery can be detected in up to 40%
of patients.28 Therefore, the protocol was amended to
include patients who had 1 to 3 MRI-detectable metasta-
ses for whom surgery was indicated for a dominant or
symptomatic tumor, and SRS was an option for all
remaining lesions. WBRT was withheld until patients
developed recurrent disease.
All patients underwent resection of a dominant or
single metastasis. Surgery was regarded as the best treat-
ment option considering 1 or more of the following cri-
teria: 1) tumor volume, 2) symptoms from mass effect or
edema, or 3) need for histologic diagnosis. Advanced sur-
gical techniques—including image guidance, microsur-
gery, tractography, and brain mapping—achieved gross
total resection while minimizing the risk to surrounding
brain (Fig. 1).
After metastasis resection and histologic confirma-
tion by frozen section, 1 to 8 carmustine wafers were used
to line the tumor cavity. Water-tight dural closure, known
to decrease complications,25 was used routinely. Ventricu-
lar openings <1 cm2 were sealed with resorbable hemo-
static material.21 Chemowafers were avoided in the
subarachnoid space, especially if the neurosurgeon
encountered a major cerebral artery or infiltration of tu-
mor. Corticosteroids and anticonvulsants were prescribed
judiciously by the treating physician.21,25
Within 14 days before surgery, patients underwent
baseline assessment, including history, physical examina-
tion, MRI, NCF, activities of daily living (ADL), KPS,
and RPA classification.27 A list of concurrent medications
was maintained. An MRI was obtained within 48 hours
after surgery; then, follow-up MRI, NCF, ADL, KPS,
RPA classification, and toxicity assessments were obtained
at months 2, 4, 6, 9, and 12. Patients were followed for 12
months unless there was evidence of treatment failure (eg,
local recurrence), neurologic decline because of CNS me-
tastases, withdrawal from the study, or death.
The NCF assessment comprised 3 domains: 1)
memory using the revised Hopkins Verbal Learning Test,
2) executive function using the Controlled Oral Word
Association and Trailmaking Test B, and 3) fine motor
coordination using the pegboard dominant and nondomi-
nant hand tests.29,30
Postsurgical imaging studies were reviewed for evi-
dence of CNS recurrence.25 Local recurrences were
defined as within 2 cm of the initial resection cavity. Dis-
tant CNS recurrences were defined as any of the follow-
ing: >2 cm from the initial surgical site; or the
contralateral side; or in the posterior fossa, spinal cord,
or cerebrospinal fluid (carcinomatous meningitis).
Adverse events (AEs) were graded for severity (mild,
moderate, severe, or fatal) and attribution (unlikely, pos-
sibly, probably, or definitely related to CW use). Toxic-
ities were graded using National Cancer Institute
Common Toxicity Criteria, version 2.0.25
The trial design was based on statistical assumptions:
a 35% rate of neurocognitive decline within 12 months, a
20% rate of local recurrence within 12 months, and a
15% drop-out rate. Accordingly, 50 to 58 patients were
required for a 2-sided 95% confidence interval (CI).
NCF endpoints included standardized score changes
(from baseline) for each visit, including time and severity
of neurocognitive change. Each NCF domain had an aver-
age standardized Z-score, and changes from each patient’s
own baseline were analyzed using the t test for paired data
(with 95% CIs). Preservation of NCF was defined as a
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decrease of 1 standard deviation (SD), any improve-
ment, or no change (0 SD); and worsening was defined as
a decrease >1 SD. Deterioration in NCF was defined as
deterioration from baseline in at least 2 domains. For each
domain, deterioration occurred if a Z-score average
decreased from baseline by 3 SD on 2 consecutive visits
or at the last follow-up visit. For a missing NCF evalua-
tion, if the reason was “neurologic,” then a score of 25.00
was imputed.
Other endpoints included the rates of local and distal
tumor recurrence; the time to recurrence; and the correla-
tion of recurrence with mass effect, cognitive functioning,
and clinical symptoms. The time to recurrence was ana-
lyzed using the Kaplan-Meier method.31 Univariate and
multivariate Cox proportional hazard models for the time
to local, distant, and overall recurrence were produced
using 11 predictive factors (baseline tumor volume, age,
RPA classification, KPS, NCF score, resected tumor vol-
ume, number of implanted wafers, number of metastatic
tumors, primary cancer type, and radiation sensitivity).
RESULTS
Eighty-two patients were screened, 69 were enrolled, and
59 received treatment (Fig. 2, Table 1). Patients were fol-
lowed for a median of 7.7 months. Fourteen of 59
patients (24%) completed the 12-month assessment pe-
riod; 5 (36%) initially had an RPA classification of 1, and
9 (64%) initially had an RPA classification of 2. Five
patients were excluded from efficacy analyses because of
protocol violations after wafer implantation.
Preservation or improvement of NCF was observed
in all 3 domains for the majority of patients throughout
the study (month 2, 26 of 46 patients [57%]; month 4, 24
of 37 patients [65%]; month 6, 17 of 26 patients [65%];
month 9, 14 of 22 patients [64%]; and month 12, 9 of 14
patients [64%]). In 1 patient (2%), NCF deterioration
was observed in the fine motor coordination domain at
months 2 and 4 and in the memory domain at month 4
(last follow-up visit).
For the individual domains, the cumulative rates of
preservation and worsening of NCF were determined. In
the memory domain, 37 of 54 patients (69%) had preser-
vation of NCF (including 26 of 54 patients [48%] who
had improvement), 8 of 54 patients (15%) had worsening
NCF, and 9 patients were not assessed. In the executive
function domain, 39 of 54 patients (72%) had preserva-
tion of NCF (including 23 of 54 patients [43%] who had
improvement), 4 of 54 patients (7%) had worsening
Figure 1. Preoperative and postoperative magnetic resonance images (MRIs) are shown. A patient with metastatic melanoma
developed aphasia and facial weakness. (A) The 3-dimensional preoperative model reveals the tumor (green), the primary motor
cortex (red) and arcuate fasciculus (purple), the Broca speech area (yellow), and the corticospinal tract (purple). (B) This preop-
erative sagittal MRI reveals a single hemorrhagic metastasis (arrows) in the left frontal lobe near the primary motor and the
Broca speech areas. (C) This postoperative MRI reveals resection of the tumor and intracavitary placement of the carmustine
wafers. Speech, motor, and neurocognitive function returned postoperatively. (D) A follow-up scan shows no tumor recurrence at
34 months.
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NCF, and 11 patients were not assessed. In the fine motor
coordination domain, 34 of 54 patients (63%) had preser-
vation of NCF (including 27 of 54 patients [50%] who
had improvement), 11 of 54 patients (20%) had worsen-
ing NCF, and 9 patients were not assessed. Mean changes
in Z-scores are provided in Figure 3.
Fifty of our 54 patients had postbaseline MRI assess-
ments. Local recurrences (Fig. 4A) developed in 14 of 50
evaluable patients (28%). The recurrence rate varied with
histology: patients with melanoma had the lowest recur-
rence rate (7%; 1 of 15 patients), those with nonsmall cell
lung cancer had a moderate rate (24%; 5 of 21 patients),
and patients with breast cancer had the highest rate (57%;
4 of 7 patients). These differences were not statistically
significant. Univariate predictors of the time to local re-
currence were: 1) baseline total tumor volume (hazard ra-
tio [HR], 1.043; P 5 .009) and 2) the number of wafers
implanted (HR, 1.366; P 5 .040), which is also a function
of tumor volume. Significant multivariate predictors of
the time to local recurrence were: 1) baseline total tumor
volume (HR, 1.095; P 5 .001), 2) primary cancer status
(previously diagnosed and receiving systemic chemother-
apy vs newly diagnosed and no prior therapy; HR,
22.506; P 5 .013), 3) baseline KPS (HR, 0.922;
P 5 .031), and 4) baseline NCF score (HR, 1.534;
P 5 .002).
Distant recurrences (Fig. 4B) developed in 24 of 50
patients (48%) and consisted of diverse histologies,
including nonsmall cell lung cancer (33%; 7 of 21
patients), breast cancer (57%; 4 of 7 patients), and mela-
noma (53%; 8 of 15 patients). Over half of the distant
recurrences (17 of 24 recurrences) developed by month 4.
Recurrences in these patients were treated with SRS or
WBRT, and they achieved favorable oncologic control
without neurologic-related death.
The median number of wafers inserted was 5 (range,
1.5-8.0 wafers), corresponding to a dose of 38.5 mg car-
mustine. Eight patients with large tumors received the
Figure 2. Participant flow is illustrated. CNS indicates central nervous system; WBRT, whole-brain radiation therapy.
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maximum dose of 8 wafers (61.6 mg carmustine). Six
patients had the wafers removed because of a serious AE
(SAE); in 2 of those patients, the investigator believed that
the SAE was possibly, or probably, related to the chemo-
wafers, and these patients remained in the study.
The AEs reflected the morbidity of the primary can-
cer and the side effects of systemic therapy (eg, chemother-
apy, radiation therapy, paraneoplastic syndromes, etc)
(Table 2). SAEs (including deaths) were reported for 40 of
59 patients. Six patients had a total of 10 SAEs that were
considered possibly related to the chemowafers (Table 3).
None were fatal, and all resolved with appropriate surgical
or medical management; 2 SAEs (a chemowafer-related
infection and a wound infection) required removal of the
wafers, and 1 SAE (the aforementioned chemowafer-
related infection) had permanent sequelae. Nine patients
died during the study, including 1 neurologic death and 8
deaths related to the extracranial, primary cancer.
DISCUSSION
Our findings add to the growing body of evidence sup-
porting intensive local and multifocal treatment for brain
metastases12,30,32-34 with sparing of the surrounding
white matter fibers, vessels, and myelin in an effort to pre-
serve NCF.35 Neurocognitive testing provides a quantita-
tive tool for monitoring the effects of therapy and
developing tailored therapies to enhance functional well
being.36 This study is significant because it demonstrates
that: 1) the “cognitive trajectory” after craniotomy is one
of preserved or improved NCF for the majority of
patients, and 2) NCF can be improved or preserved while
achieving acceptable rates of LC with a strategy of resec-
tion plus chemowafer, while deferring WBRT. Such an
TABLE 1. Patient Demographics and Cancer His-







Age: Median [range], y 63 [37-81]
Race
White 55 (93)
Black or African American 1 (2)
Asian 2 (3)
American Indian or Alaska Native 1 (2)
RPA classification (n 5 54)
Class 1 19 (35)
Class 2 35 (65)








Newly diagnosed, no prior therapy 18 (31)








Abbreviations: MRI, magnetic resonance imaging; NSCLC, non-small cell
lung cancer; RPA, recursive partitioning analysis.
Figure 3. Improvement in neurocognitive function was meas-
ured after surgical resection and carmustine wafer placement
for brain metastasis using average, standardized Z-scores
(indicated as the mean change with 95% confidence interval
[CI]). Statistically significant changes were noted in (A)
memory (a, P 5.001; b, P 5.029) and (B) executive function
(a, P 5.001; b, P 5.0007; c [left], P 5.041; c [right], P 5.018).
(C) Fine motor skills.
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approach may be particularly appropriate when surgery is
clinically indicated for a larger tumor (2-3 cm in greatest
dimension), a symptomatic metastasis, or a lesion requir-
ing tissue diagnosis.37
Brain metastases represent an increasing health pri-
ority because of the prolonged survival of cancer patients,
the inability of some novel cancer therapies to reach the
CNS, and enhanced detection using advanced neuroi-
maging.2,28 Thus, as the outlook for meaningful survival
has increased with improved systemic therapy, the goals of
brain metastasis therapy are shifting from short-term pal-
liation to prolonged control of intracerebral tumor
growth while maintaining=improving neurologic and
functional status and avoiding the potential toxicity of
WBRT.12,18,19,32,33,37,38 Indeed, results from the Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) 22952-26001 trial (surgery=SRS then WBRT
or surveillance) support withholding the upfront use of
WBRT, thereby improving functional outcomes, without
compromising survival.12,32
The current results suggest that deferring WBRT
while using upfront surgery and carmustine wafers can
preserve NCF and provide acceptable local cancer control
rates, similar to surgery and WBRT.7,12 We observed a
global NCF decline in only 1 patient (2%), which is
markedly superior to WBRT.12,29,30,32 NCF was pre-
served in all 3 domains in 65% of patients. In addition,
NCF improvements were observed in >40% of patients
for each individual domain, especially executive function
and memory. The improvement may be caused by a
reduction of perilesional vasogenic edema or the neuro-
plasticity of white matter fiber tracts. These findings
Figure 4. These are Kaplan-Meier curves for (A) local recur-
rence and (B) distant recurrence. The median time to distant
recurrence was 8.5 months.
TABLE 2. Incidence of Treatment-Emergent
Adverse Events in 5% of Patients: Treated Popula-
tion (n 5 59)
Variable No. of Patients (%)
No. with 1 treatment-emergent adverse event 53 (90)
Hematologic disorders 5 (9)
Anemia 3 (5)
Cardiac disorders 5 (9)
Bradycardia 3 (5)
Eye disorders 5 (9)
Vision blurred 3 (5)




General disorders and administration site conditions 25 (42)
Asthenia 7 (12)
Fatigue 13 (22)




Oral candidiasis 3 (5)
Metabolic disorders 23 (39)
Anorexia 3 (5)
Dehydration 4 (7)
Failure to thrive 3 (5)
Hyperglycemia 17 (29)
Musculoskeletal disorders 10 (17)
Muscular weakness 6 (10)
Neoplasms: Benign, malignant, and unspecified 5 (9)
Malignant neoplasm progression 3 (5)





Psychiatric disorders 12 (20)
Anxiety 4 (7)
Confusional state 3 (5)
Insomnia 3 (5)
Respiratory disorders 16 (27)
Dyspnea 6 (10)
Cutaneous disorders 11 (19)
Drug-induced rash 4 (7)
Vascular disorders 10 (17)
Deep vein thrombosis 6 (10)
Hypertension 4 (7)
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compare favorably to a recent study of SRS with=without
WBRT, in which memory and learning declined in 24%
of patients who underwent SRS alone and in 52% of those
who underwent SRS with WBRT.30
For patients with brain metastases, NCF scores cor-
relate with tumor volume and predict survival32; >90%
of patients with brain metastases demonstrate impairment
of 1 neurocognitive tests at baseline,32,36 which can be
improved with surgery.37 The current study demonstrates
a sustained improvement in NCF after surgery and indi-
cates that carmustine chemowafers do not adversely affect
NCF.
The 28% local recurrence rate reported here is com-
parable to the previously reported rates for SRS alone32
and for surgery with WBRT7 and is generally superior to
the rates reported from studies of surgery alone (without
wafer).7,32 The addition of WBRT to SRS increases LC
rates13,32 up to 97% for low-volume metastases.39 Previ-
ously, WBRT combined with surgery plus chemowafers
produced complete (100%) LC.25 Because local recur-
rence rates are a function of both tumor volume and surgi-
cal technique,40,41 the extent to which local efficacy is
attributable to advances in neurosurgical technology40,41
versus the effect of the carmustine wafer42 cannot be
determined without a controlled comparative trial.
There were 9 deaths during the 12-month follow-up
period, and 5 of those deaths occurred >300 days after
surgery. It is noteworthy that only 1 patient (2%) died
because of neurologic disease progression. In the EORTC
study of surgery=SRS plus WBRT, neurologic death
occurred in 28% of patients who received WBRT com-
pared with 44% of patients who were managed with sur-
veillance, although overall survival was unchanged.32 The
low neurologic mortality rate compares favorably with
patients who underwent SRS alone, reported as 12%.33
The toxicity and AEs reported here are largely
because of the systemic cancer and concurrent therapies.
Because the chemowafers release carmustine locally, there
is no detectable level of chemotherapy in the bloodstream,
avoiding many of the systemic toxicities.20-22 It is known
that chemowafers carry neurosurgical risks of cerebral
edema, wound dehiscence, or seizures,20,21 which are
reduced by the judicious use of steroids, water-tight dural
closures, and anticonvulsant medications.20,21,25 In our
prior study of chemowafers, surgery, and WBRT, we
observed seizures in 2 patients (8%), but no other
toxicities.25
The current study has limitations. First, this was not
a randomized, controlled trial. The specific bene-
fits=toxicities of surgery, chemotherapy, SRS, and avoid-
ance of WBRT were compared with historic controls.
Placebo-controlled trials using chemowafers, which have
proven efficacy in high-grade gliomas,20,22 are problem-
atic to design for single and oligometastatic brain cancer,
for which there are multiple existing options (eg, surgery
alone, SRS alone, resection plus SRS, resection plus
WBRT) and deeply held biases.18 Second, single-arm
studies of NCF in patients with brain metastases are diffi-
cult to interpret because of numerous confounding varia-
bles, including selection bias.43 In the current study, there
was a selection bias, because our patients had an RPA clas-
sification of 1 or 2, a favorable KPS, and a prognosis that
favored undergoing craniotomy. Nevertheless, each
patient acted as their own control, so an immediate post-
operative and sustained improvement in NCF is notewor-
thy and novel. Current approaches to the treatment of
brain metastases must balance local and distant control in
the CNS with neurocognitive preservation. The current
study demonstrates that the strategy of neurosurgical
resection plus chemowafers provides local cancer control
comparable to that provided by radiation therapy. Fur-
thermore, the results indicate a benefit in NCF from with-
holding WBRT and treating limited brain metastases in a
targeted manner. The range of options for patients with
brain metastases also will be increased as the novel,
pathway-specific, targeted agents44 are evaluated. The
TABLE 3. Serious Adverse Events
Patient No. Serious Adverse Event Severity Related to Wafers? Outcome
1 Intracranial hypotension Severe Probably Resolved
Soft tissue necrosis Severe Probably Resolved
2 Chemowafer-related infection Severe Probably Resolved with sequelae (wafers removed)
3 Wound infection Severe Probably Resolved (wafers removed)
4 Asthenia Moderate Possibly Resolved
Dehydration Moderate Possibly Resolved
Convulsion Moderate Possibly Resolved
5 Brain abscess Severe Possibly Resolved
6 Mental status change Moderate Possibly Resolved
Convulsion Severe Possibly Resolved
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preserved and often improved NCF observed using resec-
tion and local carmustine wafers, as well as the known
pharmacokinetics of carmustine,20,21,42 suggest that this
strategy can be used without injury to white matter fiber
tracts that affect NCF.45
FUNDING SUPPORT
This work was supported by a research grant from Eisai Inc.
MedVal Scientific Information Services, LLC, provided editorial
support for article preparation, funded by Eisai Inc. Dr. Ewend’s
time was supported by the Weatherspoon Eminent Distinguished
Professorship in Neurosurgery. Eisai provided funds to the Moffitt
Cancer Center to conduct the clinical trial and support Dr. Brem as
principal investigator, including authorship of the manuscript.
Funding to support open access for this article was provided by
Arbor Pharmaceuticals
CONFLICT OF INTEREST DISCLOSURES
Dr. Meyers has received compensation as a consultant to Eisai Inc.
Dr. Palmer is an employee of Eisai Inc. Dr. Booth-Jones received a
grant, consulting fees, and travel support from Eisai Inc. Dr. Ewend
has received research funding from Eisai Inc. and from Northwest
Biotherapeutics. Dr Ewend’s wife has acted as an unpaid consultant
to Sanofi Oncology, Wyeth=Pfizer, Genentech, Bristol-Myers
Smith, Novartis, Amgen, and GlaxoSmithKline.
REFERENCES
1. Barnholtz-Sloan JS, Yu C, Sloan AE, et al. A nomogram for individ-
ualized estimation of survival among patients with brain metastasis.
Neuro Oncol. 2012;14:910-918.
2. Claus EB. Neurosurgical management of metastases in the central
nervous system. Nat Rev Clin Oncol. 2012;9:79-86.
3. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain
RK. The biology of brain metastases-translation to new therapies.
Nat Rev Clin Oncol. 2011;8:344-356.
4. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preven-
tive and therapeutic targets. Nat Rev Cancer. 2011;11:352-363.
5. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-the role
of tumor-stroma interactions in metastasis to different organs. Int J
Cancer. 2011;128:2527-2535.
6. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of sur-
gery in the treatment of single metastases to the brain. N Engl J
Med. 1990;322:494-500.
7. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy
in the treatment of single metastases to the brain: a randomized trial.
JAMA. 1998;280:1485-1489.
8. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the
management of brain metastasis. J Clin Oncol. 2006;24:1295-1304.
9. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-
brain radiation therapy for brain metastases correlates with survival
and improved neurocognitive function. J Clin Oncol. 2007;25:1260-
1266.
10. Brem SS, Bierman PJ, Brem H, et al. Central nervous system can-
cers. J Natl Compr Canc Netw. 2011;9:352-400.
11. Mehta M. The dandelion effect: treat the whole lawn or weed selec-
tively? J Clin Oncol. 2011;29:121-124.
12. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisa-
tion for Research and Treatment of Cancer phase III trial of adju-
vant whole-brain radiotherapy versus observation in patients with 1
to 3 brain metastases from solid tumors after surgical resection or
radiosurgery: quality-of-life results. J Clin Oncol. 2013;31:65-72.
13. Rades D, Panzner A, Dziggel L, Haatanen T, Lohynska R, Schild
SE. Dose-escalation of whole-brain radiotherapy for brain metastasis
in patients with a favorable survival prognosis. Cancer. 2012;118:
3852-3859.
14. Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic
radiosurgery, whole-brain radiotherapy, or both for patients present-
ing with a limited number of brain metastases. Cancer. 2012;118:
2486-2493.
15. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus
whole-brain radiation therapy vs stereotactic radiosurgery alone for
treatment of brain metastases: a randomized controlled trial. JAMA.
2006;295:2483-2491.
16. Shibamoto Y, Baba F, Oda K, et al. Incidence of brain atrophy and
decline in mini-mental state examination score after whole-brain
radiotherapy in patients with brain metastases: a prospective study.
Int J Radiat Oncol Biol Phys. 2008;72:1168-1173.
17. Monaco EA III, Faraji AH, Berkowitz O, et al. Leukoencephalop-
athy after whole-brain radiation therapy plus radiosurgery versus
radiosurgery alone for metastatic lung cancer. Cancer. 2013;119:226-
232.
18. Khan AJ, Dicker AP. On the merits and limitations of whole-brain
radiation therapy. J Clin Oncol. 2013;31:11-13.
19. Greene-Schloesser D, Robbins ME. Radiation-induced cognitive
impairment-from bench to bedside. Neuro Oncol. 2012;14(suppl 4):
37-44.
20. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of
safety and efficacy of intraoperative controlled delivery by biodegrad-
able polymers of chemotherapy for recurrent gliomas.The Polymer-
Brain Tumor Treatment Group. Lancet. 1995;345:1008-1012.
21. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmus-
tine wafers (Gliadel) alone or in combination with chemoradiother-
apy: the French experience. Ann Surg Oncol. 2010;17:1740-1746.
22. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K.
Chemotherapy wafers for high grade glioma [serial online]. Cochrane
Database Syst Rev. 2011;(3):CD007294.
23. Ewend MG, Williams JA, Tabassi K, et al. Local delivery of chemo-
therapy and concurrent external beam radiotherapy prolongs survival
in metastatic brain tumor models. Cancer Res. 1996;56:5217-5223.
24. Ewend MG, Sampath P, Williams JA, Tyler BM, Brem H. Local
delivery of chemotherapy prolongs survival in experimental brain
metastases from breast carcinoma. Neurosurgery. 1998;43:1185-1193.
25. Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain
metastasis with resection, intracavity carmustine polymer wafers, and
radiation therapy is safe and provides excellent local control. Clin
Cancer Res. 2007;13:3637-3641.
26. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories
after postoperative delirium. N Engl J Med. 2012;367:30-39.
27. Sperduto PW, Kased N, Roberge D, et al. Summary report on the
graded prognostic assessment: an accurate and facile diagnosis-
specific tool to estimate survival for patients with brain metastases. J
Clin Oncol. 2012;30:419-425.
28. Hanssens P, Karlsson B, Yeo TT, Chou N, Beute G. Detection of
brain micrometastases by high-resolution stereotactic magnetic reso-
nance imaging and its impact on the timing of and risk for distant
recurrences. J Neurosurg. 2011;115:499-504.
29. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and
progression in patients with brain metastases treated with whole-
brain radiation and motexafin gadolinium: results of a randomized
phase III trial. J Clin Oncol. 2004;22:157-165.
30. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients
with brain metastases treated with radiosurgery or radiosurgery plus
whole-brain irradiation: a randomised controlled trial. Lancet Oncol.
2009;10:1037-1044.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete ob-
servation. J Am Stat Assoc. 1958;53:457-481.
32. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain
radiotherapy versus observation after radiosurgery or surgical resec-
tion of 1 to 3 cerebral metastases: results of the EORTC 22952-
26001 study. J Clin Oncol. 2011;29:134-141.
33. Rush S, Elliott RE, Morsi A, et al. Incidence, timing, and treatment
of new brain metastases after Gamma Knife surgery for limited brain
disease: the case for reducing the use of whole-brain radiation ther-
apy. J Neurosurg. 2011;115:37-48.
Neurocognition and Brain Metastases/Brem et al
Cancer November 1, 2013 3837
34. Chen X, Xiao J, Li X, et al. Fifty percent patients avoid whole brain
radiotherapy: stereotactic radiotherapy for multiple brain metastases.
A retrospective analysis of a single center. Clin Trans Oncol. 2012;
14:599-605.
35. Nazem-Zadeh MR, Chapman CH, Lawrence TL, Tsien CI, Cao Y.
Radiation therapy effects on white matter fiber tracts of the limbic
circuit. Med Phys. 2012;39:5603-5613.
36. Witgert ME, Meyers CA. Neurocognitive and quality of life meas-
ures in patients with metastatic brain disease. Neurosurg Clin North
Am. 2011;22:79-85.
37. Al-Shamy G, Sawaya R. Management of brain metastases: the indis-
pensable role of surgery. J Neurooncol. 2009;92:275-282.
38. Patel TR, Knisely JP, Chiang VL. Management of brain metastases:
surgery, radiation, or both? Hematol Oncol Clin North Am. 2012;26:
933-947.
39. Shehata MK, Young B, Reid B, et al. Stereotactic radiosurgery of
468 brain metastases 2 cm: implications for SRS dose and whole
brain radiation therapy. Int J Radiat Oncol Biol Phys. 2004;59:87-93.
40. Yoo H, Kim YZ, Nam BH, et al. Reduced local recurrence of a sin-
gle brain metastasis through microscopic total resection. J Neurosurg.
2009;110:730-736.
41. Patel AJ, Suki D, Hatiboglu MA, et al. Factors influencing the risk
of local recurrence after resection of a single brain metastasis. J Neu-
rosurg. 2010;113:181-189.
42. Arifin DY, Lee KY, Wang CH, Smith KA. Role of convective flow
in carmustine delivery to a brain tumor. Pharm Res. 2009;26:2289-
2302.
43. Vordermark D. Avoiding bias in the prospective evaluation of
patients with brain metastases. J Clin Oncol. 2007;25:4023-4025.
44. Lim E, Lin NU. New insights and emerging therapies for breast can-
cer brain metastases. Oncology (Williston Park). 2012;26:652-659,
663.
45. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of
chemotherapy-induced structural changes in cerebral white matter
and its correlation with impaired cognitive functioning. J Clin Oncol.
2012;30:274-281.
Original Article
3838 Cancer November 1, 2013
